Abstract
The recent announcement of the first and only FDA-approved medication (mavacamten) for the treatment of the obstructive form of hypertrophic cardiomyopathy (HCM) is exciting and motivating. Mavacamten is an allosteric and reversible inhibitor selective for cardiac myosin, an important protein in HCM development. Jerry Madukwe, the Editor-in-Chief of Trends in Pharmacological Sciences asked experts in the cardiovascular field to reflect on some of the global challenges and opportunities in translating basic and preclinical research discoveries into new treatments.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
